Melanoma and Other Malignant Neoplasms of Skin Active Not Recruiting Phase 1 / 2 Trials for GSK-2636771 (DB11795)

IndicationStatusPhase
DBCOND0081890 (Melanoma and Other Malignant Neoplasms of Skin)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03131908Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossTreatment